Šmahelová Jana, Kaštánková Iva, Poláková Kateřina Machová, Klamová Hana, Zemanová Karla, Tachezy Ruth, Hamšíková Eva, Šmahel Michal
Department of Immunology, Institute of Hematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic.
Oncol Rep. 2017 Jan;37(1):547-554. doi: 10.3892/or.2016.5226. Epub 2016 Nov 7.
As the extent of centrosome abnormalities in chronic myeloid leukemia (CML) correlates with disease stage and karyotype alterations, abnormal expression of genes encoding centrosomal proteins may be an early prognostic marker of disease progression. In the present study, we showed that in comparison with healthy controls, the expression of four centrosomal genes (AURKA, HMMR, PLK1 and ESPL1) in the peripheral blood of CML patients was significantly enhanced at diagnosis and decreased to the basal level in most patients treated with imatinib mesylate for three months. In the remaining patients (17%), this decrease was delayed and was associated with worse overall survival. The detection of antibodies in sera showed that patients with higher overall antibody production had superior outcomes in terms of achieving major molecular response and failure-free survival. These data suggest that the dynamics of the response of centrosomal genes should be considered as a risk factor and immunity against centrosomal proteins may contribute to treatment response.
